ISRG Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 27.89% compared to Intuitive Surgical, Inc.'s net margin of 14.91%. Intuitive Surgical, Inc.'s return on equity of 16.59% beat Boston Scientific Corp.'s return on equity of 12.46%.

Intuitive Surgical, Inc. has a consensus price target of $611.82, signalling upside risk potential of 21.34%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 33.01%. Given that Boston Scientific Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Boston Scientific Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Intuitive Surgical, Inc. quarterly revenues are $2.9B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Intuitive Surgical, Inc.'s net income of $799.5M is higher than Boston Scientific Corp.'s net income of $755M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 63.98x while Boston Scientific Corp.'s PE ratio is 50.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 18.17x versus 7.22x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 27.89% compared to Intuitive Surgical, Inc.'s net margin of 15.47%. Intuitive Surgical, Inc.'s return on equity of 16.59% beat Globus Medical, Inc.'s return on equity of 10.08%.

Intuitive Surgical, Inc. has a consensus price target of $611.82, signalling upside risk potential of 21.34%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 18.18%. Given that Intuitive Surgical, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Globus Medical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Intuitive Surgical, Inc. quarterly revenues are $2.9B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Intuitive Surgical, Inc.'s net income of $799.5M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 63.98x while Globus Medical, Inc.'s PE ratio is 29.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 18.17x versus 4.51x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 27.89% compared to Intuitive Surgical, Inc.'s net margin of 11.84%. Intuitive Surgical, Inc.'s return on equity of 16.59% beat Stryker Corp.'s return on equity of 15.17%.

Intuitive Surgical, Inc. has a consensus price target of $611.82, signalling upside risk potential of 21.34%. On the other hand Stryker Corp. has an analysts' consensus of $426.15 which suggests that it could grow by 15.25%. Given that Intuitive Surgical, Inc. has higher upside potential than Stryker Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Stryker Corp..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.88 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.9B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Intuitive Surgical, Inc.'s net income of $799.5M is lower than Stryker Corp.'s net income of $849M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 63.98x while Stryker Corp.'s PE ratio is 43.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 18.17x versus 5.69x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 27.89% compared to Intuitive Surgical, Inc.'s net margin of 17.41%. Intuitive Surgical, Inc.'s return on equity of 16.59% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Intuitive Surgical, Inc. has a consensus price target of $611.82, signalling upside risk potential of 21.34%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 49.58%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.669, which suggesting that the stock is 66.867% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.37% to investors and pays a quarterly dividend of $0.22 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.9B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Intuitive Surgical, Inc.'s net income of $799.5M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 63.98x while West Pharmaceutical Services, Inc.'s PE ratio is 34.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 18.17x versus 5.58x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.